In Situ Hybridization Market Size

In Situ Hybridization Market size was over USD 1.82 billion in 2024 and is poised to reach USD 7.76 billion by the end of 2037, witnessing around 11.8% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of in situ hybridization is assessed at USD 1.99 billion.

The reason behind the growth is due to the rising incidence of cancer across the globe. Fluorescence in situ hybridization also known as FISH scans cells for alterations in genes can aid in cancer diagnosis and can be used to track treatment response and illness remission. In 2040, there will likely be more than 28 million new instances of cancer worldwide.

The growing technological advancements in In-vitro diagnostics (IVD) are believed to fuel the market growth. For instance, Artificial intelligence (AI) technology integration in oncology-based in vitro diagnostic (IVD) technologies has the potential to significantly enhance healthcare decisions by identifying disease signatures that can aid in early detection and treatment, and by identifying central nervous system (CNS) cancers by predicting which therapy responses will be most successful using patient samples.

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of in situ hybridization is assessed at USD 1.99 billion.

The in situ hybridization market size was over USD 1.82 billion in 2024 and is poised to reach USD 7.76 billion by the end of 2037, witnessing around 11.8% CAGR during the forecast period i.e., between 2025-2037. The rising incidence of cancer across the globe and the growing technological advancements in In-vitro diagnostics (IVD) will drive the market growth.

North America industry is poised to account for largest revenue share 45% by 2037, impelled by increasing spending in healthcare in the region.

The major players in the market are Thermo Fisher Scientific Inc., Abbott, PerkinElmer, Inc., Leica Biosystems Nussloch GmbH, F. Hoffman-La Roche Limited, NeoGenomics Laboratories, Inc., Advanced Cell Diagnostics, Inc., BioView, Agilent Technologies, Inc., Merck KGaA, Bio-Rad Laboratories, Inc., Oxford Gene Technology IP Limited, and others.

In Situ Hybridization Market Size